In 4,885 kidney transplant recipients prescribed rapamycin, median survival age was 64.6 years, close to 64.3 without it

What the research found

GeroScience published a registry study on 5 November 2026. Stewart and Fitzsimmons used US organ-transplant records to compare survival age in kidney recipients who were alive with a working graft one year after transplant. They compared 4,885 recipients prescribed rapamycin, an mTOR-inhibitor immunosuppressant, with 6,589 recipients not prescribed it. Follow-up was a median of 11 years, and 6,443 people died. After propensity-score weighting for age, body mass index, diabetes, and 15 other factors, median survival age was 64.6 years with rapamycin and 64.3 years without it. The 95 percent confidence interval for the difference ran from −1.6 to 2.0 years, so the ages were statistically similar. The authors say they did not see a meaningful long-term survival gain from mTOR inhibition in this group. Mouse lifespan experiments are background only. This is not a trial in healthy adults, and rapamycin here is a prescribed transplant drug. Stewart reports consulting for Hansa Biopharma and Veloxis, and Fitzsimmons for Veloxis, argenx, the Transplant Therapeutics Consortium, x-Care, and Eledon, all described as unrelated to this study. DOI 10.1007/s11357-026-02643-8. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.

Evidence level: Animal study. Results in animals or cells often don't carry over to people.

Read the original at GeroScience